LCM
AGIO icon

Lynx1 Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Lynx1 Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127M Buy
3,408,937
+797,369
+31% +$24.2M 14.62% 4
2026
Q1 		$88.3M Buy
2,611,568
+2,531,944
+3,180% +$71.8M 13.96% 4
2025
Q4 		$2.17M Buy
+79,624
New +$2.79M 0.44% 13

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lynx1 Capital Management's AGIO Position: Q2 2026 in Review

Lynx1 Capital Management increased its Agios Pharmaceuticals (AGIO) stake by 31% in Q2 2026, buying an estimated $24.2M and bringing the position to 3,408,937 shares worth $127M. The position accounts for 14.62% of the portfolio, ranked #4.

Lynx1 Capital Management first reported a position in AGIO in Q4 2025 and has held it in 3 quarters since. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Lynx1 Capital Management held 3,408,937 shares of Agios Pharmaceuticals worth $127M as of Q2 2026.
  • Lynx1 Capital Management bought 797,369 Agios Pharmaceuticals shares in Q2 2026, an estimated $24.2M.
  • Agios Pharmaceuticals made up 14.62% of Lynx1 Capital Management's portfolio in Q2 2026, its #4 holding.
  • Lynx1 Capital Management first reported a position in Agios Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.